Teva Tests Biosimilar Version of Roche's Rituxan
Teva Pharmaceutical Industries (Tikva, Israel) is developing a generic version of Roche's (Basel, Switzerland) blockbuster antibody drug Rituxan, in what may possibly be the first US generic version of a monoclonal antibody.
Teva Pharmaceutical Industries (Tikva, Israel) is developing a generic version of Roche's (Basel, Switzerland) blockbuster antibody drug Rituxan, in what may possibly be the first US generic version of a monoclonal antibody.
Teva is recruiting 60 patients in Germany and Hungary for a clinical trial comparing Roche's original product with its copy, known as TL011, in patients with rheumatoid arthritis. The study is due for completion in August 2011, according to a post on clinicaltrials.gov.
Teva's partner Lonza (Basel, Switzerland) was also involved in the trial and the drug is expected to be launched in the second half of 2014, assuming positive results in development and approval from regulators.
Rituxan, also known as MabThera, is marketed for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia. It is one of the older antibody drugs that generics companies are now eyeing as a major sales opportunity.
With the global market for branded biologic drugs worth more than $80 billion a year and roughly $50 billion of that business set to lose patent protection by 2015 or 2016, biosimilars like Rituxan are an enticing prospect.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
